SM

Sanjay Mathur

Active Director Director DIN 01156748
DIN 01156748 First appointment Oct 2002 Primary industry Trading
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2002
Shareholding value •••• Premium profile

About Sanjay Mathur

Data last updated:

Sanjay Mathur is a Director at Allentis Pharmaceuticals Private Limited (since 2002). The company operates in Trading. Allentis Pharmaceuticals Private Limited reported revenue of ₹5.39 Cr (FY 2025).

DIN 01156748
Primary Designation Director
Industry Trading
First Appointment 16 Oct 2002
Oldest Company Age 24 yrs
Largest company Allentis Pharmaceuticals Private Limited · ₹5.39 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director16 Oct 20022002₹5.39 Cr (FY 2025)Active

Board colleagues of Sanjay Mathur

Directorship timeline

Open interactive timeline →
Allentis Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Sanjay Mathur

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sanjay Mathur

Sanjay Mathur currently holds 1 directorship: Allentis Pharmaceuticals Private Limited (Director, since 16 Oct 2002, revenue ₹5.39 Cr (FY 2025)).

Sanjay Mathur was first appointed on 16 Oct 2002 as Director at Allentis Pharmaceuticals Private Limited.

The current boards of Sanjay Mathur's companies include Dilip Nathani (Allentis Pharmaceuticals Private Limited), Manoj Kumar Gurnani (Allentis Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available